JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

16.34 0.68

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

16.13

Massimo

16.38

Metriche Chiave
By Trading Economics
Entrata	-1.5M -74M
Margine di Profitto	-1,582.642
Dipendenti	205
EBITDA	1.7M -72M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+41.72% upside

Dividendi
By Dow Jones
Utili prossimi	10 nov 2025

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	583M 2.3B
Apertura precedente	15.66
Chiusura precedente	16.34

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 nov 2025, 22:13 UTC

Utili

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 nov 2025, 21:23 UTC

Utili

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 nov 2025, 23:43 UTC

Discorsi di Mercato

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 nov 2025, 23:34 UTC

Discorsi di Mercato

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 nov 2025, 21:00 UTC

Utili

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Utili

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Utili

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 nov 2025, 20:55 UTC

Utili

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Utili

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Utili

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 nov 2025, 20:46 UTC

Utili

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 nov 2025, 20:46 UTC

Utili

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 nov 2025, 20:45 UTC

Utili

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 nov 2025, 20:44 UTC

Utili

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 nov 2025, 20:43 UTC

Utili

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 nov 2025, 20:42 UTC

Utili

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 nov 2025, 20:41 UTC

Utili

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 nov 2025, 20:40 UTC

Utili

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 nov 2025, 20:39 UTC

Utili

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 nov 2025, 20:37 UTC

Utili

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 nov 2025, 20:37 UTC

Utili

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 nov 2025, 20:37 UTC

Utili

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 nov 2025, 20:36 UTC

Utili

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 nov 2025, 20:35 UTC

Utili

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 nov 2025, 20:35 UTC

Utili

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 nov 2025, 20:35 UTC

Utili

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 nov 2025, 20:34 UTC

Utili

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 nov 2025, 20:33 UTC

Utili

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 nov 2025, 14:27 UTC

Utili

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 nov 2025, 14:25 UTC

Utili

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

41.72% in crescita

Previsioni per 12 mesi

Media 23.1 USD 41.72%

Alto 44 USD

Basso 11 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.